© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Genitourinary Cancers
UGN-102 May Serve as Surgical Alternative for Low-Grade NMIBC With Intermediate Risk
May 15, 2020
"These interim data demonstrate that primary chemoablation of low-grade intermediate-risk non–muscle invasive bladder cancer using UGN-102 results in a significant treatment response and encouraging durability."
BCG-Unresponsive NMIBC Responds to Intravesical Adenoviral Gene Therapy
May 15, 2020
"Intravesical nadofaragene firadenovec [recombinant adenovirus interferon alpha achieved a 53.4% CR rate in patients with BCG-unresponsive carcinoma in situ of the bladder."
Combining Immune Checkpoint and Androgen Receptor Inhibitors Yields Positive Responses for mCRPC
April 11, 2020
Pembrolizumab plus enzalutamide in castration- resistant prostate cancer that exhibited enzalutamide resistance led to positive antitumor signals and a favorable safety profile, according to results of the phase II KEYNOTE-199 trial presented at the 2020 Genitourinary Cancers Symposium.
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 07, 2020
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Real-World PSA Response Data Similar to Clinical Trials in Prostate Cancer
April 07, 2020
Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.
Darolutamide Trial Evaluates Noninferiority to Standard Care in Intermediate-Risk Prostate Cancer
April 06, 2020
External Beam Radiation therapy with or without androgen deprivation therapy or surgery are the standards of care for men with intermediate-risk prostate cancer, but the adverse events associated with the treatments, delayed testosterone recovery and prolonged erectile dysfunction, are challenges.
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
March 30, 2020
An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care
March 30, 2020
A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
Expert Expands on Evolving Treatment Strategies for Prostate and Urothelial Cancers
March 29, 2020
At the Annual Education Summit of the Medical Oncology Association of Southern California, Tanya Dorff, MD, associate clinical professor of medicine and head of the Genitourinary Cancer Program at the City of Hope, discussed evolving practices in prostate and urothelial cancers as well as highlighted controversies in the treatment landscape such as the role of combination therapy in prostate cancer.
Liquid Biopsy Reveals Differences in DDR Genes in Prostate Cancer
March 27, 2020
Liquid biopsy results that identify DNA damage repair genes in prostate cancer may be a useful tool in clinical-deci­sion making, espe­cially because these genes can elucidate therapeutic vulnera­bilities that could be exploited by current treatments.